Literature DB >> 12391610

Region-specific reduction of A beta-degrading endopeptidase, neprilysin, in mouse hippocampus upon aging.

Nobuhisa Iwata1, Yoshie Takaki, Shinjiro Fukami, Satoshi Tsubuki, Takaomi C Saido.   

Abstract

Metabolism of amyloid-beta peptide (A beta) is closely associated with the pathology and etiology of Alzheimer's disease (AD). Neprilysin is the only rate-limiting catabolic peptidase proven by means of reverse genetics to participate in A beta metabolism in vivo. The aim of the present study is to assess whether possible spatial changes in neprilysin level in the brain with aging correlate to AD-vulnerable regions. When neprilysin levels in various brain regions of 10-, 80- and 132-week-old mice were evaluated by neprilysin-dependent endopeptidase activity assay and Western blot-based quantitative analysis, a clear change in neprilysin level with aging was observed in the hippocampal formation, in which the level was reduced by 20% at 132 weeks, compared to the 10-week group. Quantitative immunohistochemical analysis confirmed a marked local reduction of neprilysin levels with aging at the outer molecular layer and polymorphic layer of the dentate gyrus, and the stratum lucidum of the hippocampus, where the densities were reduced by 56%, 82% and 83%, respectively, at 132 weeks compared to the 10-week group. Thus, neprilysin was decreased selectively at the terminal zones and on axons of the lateral perforant path and the mossy fibers. These are the sites that show A beta pathology in mutant amyloid precursor protein (APP) transgenic mice, and that show synaptic loss in AD. The immunoreactivities to synaptic vesicle protein-2 and synaptophysin in the stratum lucidum and the dentate gyrus were unchanged, suggesting that a loss or decrease of synapses was not responsible for the decrease in the neprilysin levels. These observations suggest that downregulation of neprilysin is likely to be related to AD pathology and to the A beta deposition associated with normal aging in humans. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12391610     DOI: 10.1002/jnr.10390

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  62 in total

1.  Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy.

Authors:  Wesley Farris; Sonja G Schütz; John R Cirrito; Ganesh M Shankar; Xiaoyan Sun; Ana George; Malcolm A Leissring; Dominic M Walsh; Wei Qiao Qiu; David M Holtzman; Dennis J Selkoe
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307

2.  Neprilysin: an enzyme candidate to slow the progression of Alzheimer's disease.

Authors:  Salim S El-Amouri; Hong Zhu; Jin Yu; Robert Marr; Inder M Verma; Mark S Kindy
Journal:  Am J Pathol       Date:  2008-04-10       Impact factor: 4.307

3.  Brain estrogen deficiency accelerates Abeta plaque formation in an Alzheimer's disease animal model.

Authors:  Xu Yue; Melissa Lu; Techie Lancaster; Phillip Cao; Shin-Ichiro Honda; Matthias Staufenbiel; Nobuhiro Harada; Zhenyu Zhong; Yong Shen; Rena Li
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

Review 4.  Amyloid beta-degrading cryptidases: insulin degrading enzyme, presequence peptidase, and neprilysin.

Authors:  E Malito; R E Hulse; W-J Tang
Journal:  Cell Mol Life Sci       Date:  2008-08       Impact factor: 9.261

5.  Aging-related correlation of insulin-degrading enzyme with gamma-secretase-generated products involving insulin and glucose levels in transgenic mice.

Authors:  Dae Y Hwang; Jung S Cho; Chuel K Kim; Sun B Shim; Seung W Jee; Su H Lee; Su J Seo; Joon Y Cho; Seok H Lee; Yong K Kim
Journal:  Neurochem Res       Date:  2005-09       Impact factor: 3.996

6.  Somatostatin receptor subtype-4 agonist NNC 26-9100 decreases extracellular and intracellular Aβ₁₋₄₂ trimers.

Authors:  Karin E Sandoval; Susan A Farr; William A Banks; Albert M Crider; John E Morley; Ken A Witt
Journal:  Eur J Pharmacol       Date:  2012-03-16       Impact factor: 4.432

7.  Alterations in the Medullary Endocannabinoid System Contribute to Age-related Impairment of Baroreflex Sensitivity.

Authors:  Chris L Schaich; Hossam A Shaltout; Megan Grabenauer; Brian F Thomas; Patricia E Gallagher; Allyn C Howlett; Debra I Diz
Journal:  J Cardiovasc Pharmacol       Date:  2015-05       Impact factor: 3.105

8.  Adeno-associated viral (AAV) serotype 5 vector mediated gene delivery of endothelin-converting enzyme reduces Abeta deposits in APP + PS1 transgenic mice.

Authors:  Niki C Carty; Kevin Nash; Daniel Lee; Mary Mercer; Paul E Gottschall; Craig Meyers; Nicholas Muzyczka; Marcia N Gordon; Dave Morgan
Journal:  Mol Ther       Date:  2008-07-29       Impact factor: 11.454

Review 9.  Endothelin-converting enzymes and related metalloproteases in Alzheimer's disease.

Authors:  Javier Pacheco-Quinto; Aimee Herdt; Christopher B Eckman; Elizabeth A Eckman
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

10.  Synapses, synaptic activity and intraneuronal abeta in Alzheimer's disease.

Authors:  Davide Tampellini; Gunnar K Gouras
Journal:  Front Aging Neurosci       Date:  2010-05-21       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.